In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Voyager Therapeutics Inc’s stock clocked out at $4.03, up 1.51% from its previous closing price of $3.97. In other words, the price has increased by $1.51 from its previous closing price. On the day, 0.43 million shares were traded. VYGR stock price reached its highest trading level at $4.045 during the session, while it also had its lowest trading level at $3.91.
Ratios:
To gain a deeper understanding of VYGR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.19 and its Current Ratio is at 6.19. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
On December 02, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 03 ’25 when Jorgensen Nathan D. sold 7,666 shares for $4.78 per share. The transaction valued at 36,643 led to the insider holds 123,834 shares of the business.
Fahey Sandell Jacquelyn bought 5,843 shares of VYGR for $27,937 on Oct 03 ’25. On Oct 03 ’25, another insider, Jorgensen Nathan D., who serves as the Officer of the company, bought 7,666 shares for $4.78 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 224068352 and an Enterprise Value of 53506340. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.15 while its Price-to-Book (P/B) ratio in mrq is 1.02. Its current Enterprise Value per Revenue stands at 1.709 whereas that against EBITDA is -0.393.
Stock Price History:
The Beta on a monthly basis for VYGR is 1.25, which has changed by -0.42128283 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $7.44, while it has fallen to a 52-week low of $2.64. The 50-Day Moving Average of the stock is -11.03%, while the 200-Day Moving Average is calculated to be 7.26%.
Shares Statistics:
It appears that VYGR traded 667.99K shares on average per day over the past three months and 479560 shares per day over the past ten days. A total of 55.48M shares are outstanding, with a floating share count of 45.80M. Insiders hold about 17.63% of the company’s shares, while institutions hold 54.75% stake in the company. Shares short for VYGR as of 1763078400 were 3140206 with a Short Ratio of 4.70, compared to 1760486400 on 3217904. Therefore, it implies a Short% of Shares Outstanding of 3140206 and a Short% of Float of 6.74.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 11.0 analysts currently analyzing and rating the stock of Voyager Therapeutics Inc (VYGR).The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.3 and low estimates of -$0.62.
Analysts are recommending an EPS of between -$1.92 and -$2.29 for the fiscal current year, implying an average EPS of -$2.09. EPS for the following year is -$1.56, with 11.0 analysts recommending between -$0.64 and -$2.05.
Revenue Estimates
In. The current quarter, 12 analysts expect revenue to total $10.49M. It ranges from a high estimate of $24.03M to a low estimate of $3M. As of. The current estimate, Voyager Therapeutics Inc’s year-ago sales were $6.28MFor the next quarter, 12 analysts are estimating revenue of $9.38M. There is a high estimate of $18.3M for the next quarter, whereas the lowest estimate is $1M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $49.07M, while the lowest revenue estimate was $28.04M, resulting in an average revenue estimate of $35.53M. In the same quarter a year ago, actual revenue was $80MBased on 12 analysts’ estimates, the company’s revenue will be $61.03M in the next fiscal year. The high estimate is $140.9M and the low estimate is $4M.
